Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection
Shots:
- The P-III REGN-COV 2069 trial involves assessing the efficacy and safety of Ab cocktail (casirivimab (1200 mg- SC) + imdevimab (1200 mg- SC) vs PBO in 1-505 people to prevent symptomatic infection in household contacts of individuals infected with COVID-19
- The trial met its 1EP and 2EPs showed an 81% reduction in the risk of symptomatic infections- patients with symptomatic infection resolved symptoms (1 vs 3wk.). In a cohort of infected asymptomatic patients- Ab cocktail showed a 31% reduction in the overall risk of progressing to symptomatic COVID-19
- The companies will share the results with regulatory authorities including the EMA and the FDA
Ref: GlobeNewswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com